

Joyce A Cramer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7208334/publications.pdf>

Version: 2024-02-01

68
papers

13,834
citations

66234

42
h-index

102304

66
g-index

71
all docs

71
docs citations

71
times ranked

10796
citing authors

#	ARTICLE	IF	CITATIONS
1	A systematic review of the associations between dose regimens and medication compliance. <i>Clinical Therapeutics</i> , 2001, 23, 1296-1310.	1.1	2,040
2	Medication Compliance and Persistence: Terminology and Definitions. <i>Value in Health</i> , 2008, 11, 44-47.	0.1	1,701
3	Comparison of Carbamazepine, Phenobarbital, Phenytoin, and Primidone in Partial and Secondarily Generalized Tonic-Clonic Seizures. <i>New England Journal of Medicine</i> , 1985, 313, 145-151.	13.9	1,110
4	A Systematic Review of Adherence With Medications for Diabetes. <i>Diabetes Care</i> , 2004, 27, 1218-1224.	4.3	1,050
5	How Often Is Medication Taken as Prescribed?. <i>JAMA - Journal of the American Medical Association</i> , 1989, 261, 3273.	3.8	710
6	A Comparison of Valproate with Carbamazepine for the Treatment of Complex Partial Seizures and Secondarily Generalized Tonic-Clonic Seizures in Adults. <i>New England Journal of Medicine</i> , 1992, 327, 765-771.	13.9	688
7	Naltrexone in the Treatment of Alcohol Dependence. <i>New England Journal of Medicine</i> , 2001, 345, 1734-1739.	13.9	590
8	Development and Cross-Cultural Translations of a 31-Item Quality of Life in Epilepsy Inventory. <i>Epilepsia</i> , 1998, 39, 81-88.	2.6	563
9	A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia. <i>New England Journal of Medicine</i> , 1997, 337, 809-815.	13.9	515
10	Development of the Quality of Life in Epilepsy Inventory. <i>Epilepsia</i> , 1995, 36, 1089-1104.	2.6	496
11	Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. <i>Current Medical Research and Opinion</i> , 2005, 21, 1453-1460.	0.9	369
12	A Brief Questionnaire to Screen for Quality of Life in Epilepsy The QOLIE-10. <i>Epilepsia</i> , 1996, 37, 577-582.	2.6	305
13	Development of the Quality of Life in Epilepsy Inventory for Adolescents: The QOLIE-AD-48. <i>Epilepsia</i> , 1999, 40, 1114-1121.	2.6	222
14	The relationship between poor medication compliance and seizures. <i>Epilepsy and Behavior</i> , 2002, 3, 338-342.	0.9	198
15	Medication Compliance Feedback and Monitoring in a Clinical Trial: Predictors and Outcomes. <i>Value in Health</i> , 2003, 6, 566-573.	0.1	184
16	Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service-Related PTSD. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 493.	3.8	184
17	New Antiepileptic Drugs: Comparison of Key Clinical Trials. <i>Epilepsia</i> , 1999, 40, 590-600.	2.6	180
18	Risk Factors for Poor Health-Related Quality of Life in Adolescents with Epilepsy. <i>Epilepsia</i> , 1999, 40, 1715-1720.	2.6	177

#	ARTICLE	IF	CITATIONS
19	A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. <i>Epilepsy and Behavior</i> , 2003, 4, 124-132.	0.9	152
20	Epilepsy, Sex Hormones, and Antiepileptic Drugs. <i>Epilepsia</i> , 1985, 26, S40-51.	2.6	141
21	The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy. <i>Epilepsy and Behavior</i> , 2004, 5, 337-342.	0.9	141
22	Adverse effects of antiepileptic drugs: a brief overview of important issues. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 885-891.	1.4	133
23	Healthcare utilization and costs in adults with stable and uncontrolled epilepsy. <i>Epilepsy and Behavior</i> , 2014, 31, 356-362.	0.9	130
24	Effect of Levetiracetam on Epilepsy-Related Quality of Life. <i>Epilepsia</i> , 2000, 41, 868-874.	2.6	123
25	The Influence of Comorbid Depression on Seizure Severity. <i>Epilepsia</i> , 2003, 44, 1578-1584.	2.6	119
26	The Influence of Insulin Use on Glycemic Control: How well do adults follow prescriptions for insulin?. <i>Diabetes Care</i> , 2005, 28, 78-83.	4.3	117
27	Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. <i>Epilepsy and Behavior</i> , 2003, 4, 118-123.	0.9	115
28	The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France. <i>Clinical Therapeutics</i> , 2006, 28, 1686-1694.	1.1	99
29	Treatment Persistence and Compliance with Medications for Chronic Obstructive Pulmonary Disease. <i>Canadian Respiratory Journal</i> , 2007, 14, 25-29.	0.8	91
30	Quantitative Assessment of Seizure Severity for Clinical Trials: A Review of Approaches to Seizure Components. <i>Epilepsia</i> , 2008, 42, 119-129.	2.6	84
31	Healthcare utilization and costs in children with stable and uncontrolled epilepsy. <i>Epilepsy and Behavior</i> , 2014, 32, 135-141.	0.9	79
32	Defining minimally important change in QOLIE-31 scores: Estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures. <i>Epilepsy and Behavior</i> , 2012, 23, 230-234.	0.9	77
33	Persistence with Bisphosphonate Treatment for Osteoporosis: Finding the Root of the Problem. <i>American Journal of Medicine</i> , 2006, 119, S12-S17.	0.6	75
34	Use of an online epilepsy diary to characterize repetitive seizures. <i>Epilepsy and Behavior</i> , 2015, 47, 66-71.	0.9	72
35	Development of a new seizure severity questionnaire: initial reliability and validity testing. <i>Epilepsy Research</i> , 2002, 48, 187-197.	0.8	62
36	Differentiating anxiety and depression symptoms in patients with partial epilepsy. <i>Epilepsy and Behavior</i> , 2005, 6, 563-569.	0.9	61

#	ARTICLE	IF	CITATIONS
37	Principles of Health-related Quality of Life: Assessment in Clinical Trials. <i>Epilepsia</i> , 2002, 43, 1084-1095.	2.6	58
38	Tolerability of levetiracetam in elderly patients with CNS disorders. <i>Epilepsy Research</i> , 2003, 56, 135-145.	0.8	56
39	Relationship between medication compliance and medical outcomes. <i>American Journal of Health-System Pharmacy</i> , 1995, 52, S27-S29.	0.5	49
40	Quality of life improvement with conversion to lamotrigine monotherapy. <i>Epilepsy and Behavior</i> , 2004, 5, 224-230.	0.9	46
41	Effect of partial compliance on cardiovascular medication effectiveness. <i>British Heart Journal</i> , 2002, 88, 203-206.	2.2	45
42	Improved mood states with lamotrigine in patients with epilepsy. <i>Epilepsy and Behavior</i> , 2004, 5, 702-707.	0.9	38
43	The Personal Impact of Epilepsy Scale (PIES). <i>Epilepsy and Behavior</i> , 2015, 42, 140-146.	0.9	38
44	Women with epilepsy: Hormonal issues from menarche through menopause. <i>Epilepsy and Behavior</i> , 2007, 11, 160-178.	0.9	36
45	Is a separate monotherapy indication warranted for antiepileptic drugs?. <i>Lancet Neurology</i> , The, 2015, 14, 1229-1240.	4.9	36
46	Treatment issues for children with epilepsy transitioning to adult care. <i>Epilepsy and Behavior</i> , 2017, 69, 153-160.	0.9	33
47	The impact of seizures and adverse effects on global health ratings. <i>Epilepsy and Behavior</i> , 2007, 11, 179-184.	0.9	29
48	Mood disorders are linked to health-related quality of life in epilepsy. <i>Epilepsy and Behavior</i> , 2002, 3, 491-492.	0.9	18
49	Determining minimally important change thresholds for the Seizure Severity Questionnaire (SSQ). <i>Epilepsy and Behavior</i> , 2014, 31, 286-290.	0.9	15
50	Impact of seizure frequency reduction on health-related quality of life among clinical trial subjects with refractory partial-onset seizures: A pooled analysis of phase III clinical trials of eslicarbazepine acetate. <i>Epilepsy and Behavior</i> , 2017, 68, 203-207.	0.9	15
51	The Short-Term Impact of Adjunctive Tiagabine on Health-Related Quality of Life. <i>Epilepsia</i> , 2001, 42, 70-75.	2.6	13
52	Sensitivity testing of the Seizure Severity Questionnaire (SSQ). <i>Epilepsy and Behavior</i> , 2014, 31, 281-285.	0.9	10
53	Tolerability of antiepileptic drugs: Can we determine differences?. <i>Epilepsy and Behavior</i> , 2012, 23, 187-192.	0.9	9
54	Development of a growth hormone injection questionnaire for adolescents. <i>Journal of Adolescent Health</i> , 2004, 34, 27-29.	1.2	8

#	ARTICLE	IF	CITATIONS
55	Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate. <i>Epilepsy and Behavior</i> , 2015, 53, 149-153.	0.9	8
56	Results of a naturalistic study of treatment options: Switching atypical antipsychotic drugs or augmenting with valproate. <i>Clinical Therapeutics</i> , 2004, 26, 905-914.	1.1	7
57	Elucidating the transdiagnostic dimensional structure of trauma-related psychopathology: Findings from VA cooperative study 504 "risperidone treatment for military service related chronic post traumatic stress disorder. <i>Journal of Affective Disorders</i> , 2015, 172, 331-336.	2.0	7
58	Brief report: A quality of life instrument for adolescents with growth disorders. <i>Journal of Adolescence</i> , 2005, 28, 595-600.	1.2	6
59	Comparison of a Noninstrumented Immunoassay for Carbamazepine to High Performance Liquid Chromatography and Fluorescence Polarization Immunoassay. <i>Epilepsia</i> , 1990, 31, 480-484.	2.6	5
60	Health-related quality of life in patients treated with eslicarbazepine acetate monotherapy: Pooled analysis from two registered clinical trials. <i>Epilepsy and Behavior</i> , 2019, 92, 31-35.	0.9	4
61	Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Post hoc analyses of clinical trial results. <i>Epilepsy and Behavior</i> , 2020, 112, 107312.	0.9	4
62	Identification of seizure clusters using free text notes in an electronic seizure diary. <i>Epilepsy and Behavior</i> , 2020, 113, 107498.	0.9	3
63	Reflections on a career in epilepsy: An unplanned journey. <i>Epilepsy and Behavior</i> , 2016, 57, 217-219.	0.9	1
64	Minimum clinically important difference (MCID) of the personal impact of epilepsy scale (PIES). <i>Epilepsy and Behavior</i> , 2022, 130, 108691.	0.9	1
65	Medication Compliance in Clinical Trials. <i>Clinical Research and Regulatory Affairs</i> , 1994, 11, 47-59.	2.1	0
66	Quality of life issues for women with epilepsy. , 2003, , 35-44.		0
67	Reflections on monotherapy trials for epilepsy " Authors' reply. <i>Lancet Neurology</i> , The, 2016, 15, 657-658.	4.9	0
68	Obtaining optimal compliance with drug therapy. <i>Managed Care</i> , 2003, 12, 9-11; discussion 23-5.	0.3	0